The Efficacy of a Suppository Based On Phenolmicin P3 And Bosexil (Mictalase®) In Control of Irritative Symptoms in Patients Undergoing Thulium Laser Enucleation of Prostate: A Single-Center, Randomized, Controlled, Open Label, Phase III Study

Riccardo Bertolo (✉ riccardobertolo@hotmail.it)
“San Carlo di Nancy” Hospital – GVM Care & Research

Chiara Cipriani
“San Carlo di Nancy” Hospital – GVM Care & Research

Matteo Vittori
“San Carlo di Nancy” Hospital – GVM Care & Research

Marco Carilli
“San Carlo di Nancy” Hospital – GVM Care & Research

Francesco Maiorino
“San Carlo di Nancy” Hospital – GVM Care & Research

Valerio Iacovelli
“San Carlo di Nancy” Hospital – GVM Care & Research

Carlo Ganini
Torvergata Oncoscience Research TOR, University of Rome Tor Vergata

Michele Antonucci
“San Carlo di Nancy” Hospital – GVM Care & Research

Marta Signoretti
“San Carlo di Nancy” Hospital – GVM Care & Research

Filomena Petta
“San Carlo di Nancy” Hospital – GVM Care & Research

Massimo Panei
“San Carlo di Nancy” Hospital – GVM Care & Research

Pierluigi Bove
“San Carlo di Nancy” Hospital – GVM Care & Research

Research Article
Keywords: benign prostatic hyperplasia, BPH, laser enucleation, ThuLEP, LUTS, urinary tract infections

Posted Date: December 22nd, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1006607/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Several studies described post-operative irritative symptoms after laser enucleation of prostate, sometimes associated with urge incontinence, probably linked to laser-induced prostatic capsule irritation, and potential for lower urinary tract infections. We aimed to evaluate the efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate (ThuLEP).

**Methods:** In this single-center, prospective, randomized, open label, phase-III study, patients with indication to ThuLEP were enrolled (Dec2019-Feb2021 - Institutional ethics committee STS CE Lazio approval no.1/N-726 - ClinicalTrials.gov NCT05130918). The report conformed to CONSORT 2010 guidelines. Eligible patients were 1:1 randomized. Randomization defined Group A: patients who were administered Mictalase® suppositories twice a day for 5 days, then once a day for other 10 days; Group B: patients who did not receive Mictalase® (“controls”). Study endpoints were evaluated at 15 and 30 days postoperation. Primary endpoint included evaluation of effects of the suppository on irritative symptoms by administering IPSS+QoL questionnaire. Secondary endpoint included evaluation of effects on urinary tract infections by performance of urinalysis with urine culture.

**Results:** 111 patients were randomized: 56 in Group A received Mictalase®. Baseline and perioperative data were comparable. At 15-days, no significant differences were found in terms of IPSS+QoL scores and urinalysis parameters. A significant difference in the rate of positive urine cultures favored Group A (p=0.04). At 30-days follow-up, significant differences were found in median IPSS score (6 [IQR 3–11] versus 10 [5–13], Group A vs B, respectively, p=0.02). Urinalysis parameters and rate of positive urine cultures were not significantly different.

**Conclusions:** The present randomized trial investigated the efficacy of Mictalase® in control of irritative symptoms and prevention of lower urinary tract infections in patients undergoing ThuLEP. IPSS improvement 30-days postoperation was more pronounced in patients who received Mictalase®. Lower rate of positive urine culture favored Mictalase® group 15-days postoperatively.

The clinical trial has been registered on ClinicalTrials.gov on November 23rd, 2021 – Registration number NCT05130918.

1. Introduction

Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) are among the most common medical issues for the aging male [1]. Indeed, population-based studies have suggested that more than 40% of men aged over 60 years old suffers from BPH symptoms [2].

In patients bothered from LUTS caused by benign prostatic obstruction (BPO) refractory to medical therapy and worthy of surgical intervention, transurethral resection of the prostate (TURP) and open
prostatectomy (OP) have been the reference-standard procedures [3]. Although effective, such treatment options are burdened by several potential perioperative morbidities. Over the past three decades research focused on the development of new surgical strategies aimed to reduce morbidity and complications. Thanks to the advent of laser technologies, endoscopic enucleation of the prostate (EEP) techniques have been developed [4, 5]. They reproduce the concept of OP, but this is achieved endoscopically like TURP, using a laser instead of a finger to enucleate the adenoma. In this scenario, thulium laser enucleation of prostate (ThuLEP) has been introduced in 2010 [6] and represents a viable option suggested by the European Association of Urology (EAU) guidelines [7] in case of large BPH (> 80 ml). It has been reported that ThuLEP would either de-obstruct and reduce morbidity, catheterization time and hospital stay compared to TURP and OP [8–11]. Nevertheless, several studies described post-operative irritative symptoms after laser enucleation of prostate, sometimes associated with urge incontinence, probably linked to laser-induced prostatic capsule irritation, and potential for lower urinary tract infections [12]. These symptoms negatively impact on patients’ quality of life, and their management is controversial. In this scenario, the use of oral medical treatments and suppositories (e.g. non-steroidal anti-inflammatory drugs, anticholinergic drugs or similar) has been described with variable effectiveness [12–15].

To contribute to this field, the present study was conceived to evaluate the efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms and prevention of lower urinary tract infections in patients who underwent ThuLEP.

2. Materials And Methods

2.1 Patients

In this single-center, prospective, randomized, open label, phase-III study, patients with indication to ThuLEP for BPO were enrolled between December 1st, 2019 and February 28th, 2021 (ClinicalTrials.gov NCT05130918, registered on 23/11/2021). The study was approved by the local institutional ethics committee (no. approval STS N-726, Ethics Committee “Lazio 1”) and performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. Report of the trial conformed to the CONSORT 2010 guidelines (Figure 1) [16]. The Landis criteria were acknowledged [17].

Specifically for the purpose of the study, patients with history of prostatitis, history of neurogenic detrusor overactivity (as determined after urodynamic observation), diagnosed prostate cancer, previous surgeries of the lower urinary tract, indwelling catheter, history of nephrolithiasis, and known or suspected hypersensitivity to Phenolmicin P3 and/or Bosexil were excluded. Patients were excluded as well in case of occurrence of severe intraoperative complications.

Eligible patients were randomized in a 1:1 ratio. The randomization scheme was generated by using the Web site Randomization.com (http://www.randomization.com). After randomization, the two arms were defined as follows: Group A: patients who were administered Phenolmicin P3 and Bosexil (Mictalase®
medical device) suppositories twice a day for 5 days, then once a day for another 10 days as per the manufacturer’s instructions; Group B: patients who did not receive Mictalase® (named “controls”).

2.2 Outcomes measurements

Preoperative variables, including age, prostate volume (PVol), maximum urinary flow rate at uroflowmetry ($Q_{\text{max}}$) with post-voiding residual volume (PVR), and International Prostate Symptom Score (IPSS) with Quality of Life (QoL) were collected. Patients were categorized into three clusters (mild: 0-11 / moderate: 12-23 / severe: 24-35) based on IPSS score.

Perioperative data, including operative time, total laser energy delivered, intraoperative complications classified according to the modified Satava system (Grade 1: complications included incidents without consequences for the patient; grade 2: complications which were treated intraoperatively with endoscopic surgery (grade 2a) or required endoscopic re-treatment (grade 2b); and grade 3: complications included incidents requiring open or laparoscopic surgery) [18], length of stay, and catheterization time were recorded. Eventual complications occurring within the early postoperative follow-up (30 days) were recorded and classified according to Clavien-Dindo [19].

Study endpoints were evaluated both at 15 and 30 days post-operative follow-up. Primary endpoint included the evaluation of the eventual effects of the suppository on irritative symptoms as assessed by IPSS ad QoL questionnaires, with categorization of symptoms severity as aforementioned. Secondary endpoint included evaluation of the eventual effects of the suppository on the occurrence of urinary tract infections, assessed by performance of urinalysis with urine culture at the same time points (15 and 30 days post-operatively). Positive urine culture was reported as asymptomatic bacteriuria in patients without LUTS showing bacterial growth $< 10^5$ CFU/mL on a mid-stream sample of urine [20]. In case of positive urine culture in patients with symptoms, appropriate antimicrobial therapy was prescribed based upon antibiogram.

Finally, although beyond the purpose of the study, in order to prove the adequate de-obstructive effect of ThuLEP, regardless of the allocation arm, patients underwent uroflowmetry with PVR estimation at 30-days follow-up.

2.3. Sample size calculation

The target sample size for the primary outcome of interest was calculated assuming a 50% reduction of patients with moderate-to-severe symptoms (according to IPSS) after administration of the suppository under investigation.

Given a rate of patients with moderate-to-severe symptoms around 50% after ThuLEP (as per our previous experience), the rate was expected to drop to 25% at last follow-up in the group of patients administered with the suppository. With a 1-β power of 80% and a type I (α) error of 0.05, enrollment of 110 patients (55 per group) was required.
The sample size was adequate enough to evaluate eventual differences between the two groups in terms of postoperative alteration of the urine test at urinalysis or microscopic examination (red blood cells, white blood cells (or pus cells), bacteria (germs), and altered pH) and/or positive urine culture (100% in our experience after ThuLEP versus 50% expected in patients administered with the suppository: 8 vs 8 patients to be enrolled).

2.4 Statistical analysis

Continuous variables were summarized using medians and interquartile ranges (IQR); frequencies and proportions were used to report categorical variables. Median values of continuous variables calculated in the two study groups were compared by using the two-samples Mann Whitney test, while proportions of categorical variables were compared by using the Fisher's exact test.

Significance level was set at p-value < 0.05. Statistical analysis was performed by using “Statistic” 8.0 Software (StatSoft, Tulsa, OK, United States).

3. Results

A hundred-seventy-one consecutive patients were screened. Twenty-three patients with neurogenic detrusor overactivity, 5 with prostatitis, 10 with diagnosed prostate cancer, 3 who had undergone previous surgeries of the lower urinary tract, 2 with history of nephrolithiasis, and 16 with indwelling catheter were discarded. One patient who experienced trans-urethral resection syndrome (Satava 2a) was excluded. No patient reported either known or suspected hypersensitivity to Phenolmicin P3 and/or Bosexil.

After accounting for the exclusion criteria, 111 patients were randomized. 56 were allocated to treatment Group A and received Mictalase®; 55 were allocated to control Group B. The study flow-chart was reported in Figure 2.

Groups were comparable at baseline in all variables analyzed. Concerning the intra-operative and peri-operative data, no statistically significant differences were found between the treatment groups.

Table 1 reported the complete data about baseline patients’ characteristics, intraoperative and peri-operative data stratified by treatment group.

At 15-days follow-up, no statistically significant differences were found comparing the treatment groups in terms of IPSS and QoL scores, and urinalysis parameters. Overall, rate of positive urine cultures was comparable, but after excluding asymptomatic bacteriuria, a statistically significant difference was found in favor of Group A (p = 0.04) (Table 2 and Figure 3).

When analyzing the patients stratified by clusters of IPSS score, 15th postoperative day follow-up showed comparable rates of patients with moderate-to-severe symptoms according to the IPSS score between the groups (27/56 (48.2%) versus 24/55 (43.6%), Group A versus Group B, respectively, p = 0.6).
At 30-days follow-up, no significant differences were found in terms of QoL. Conversely, significant differences were found in the median IPSS score (6 [IQR 3 – 11] versus 10 [IQR 5 – 13], Group A vs B, respectively, p = 0.02). Figure 4 detailed the IPSS at different time points stratified by treatment groups. At reassessment of clusters of symptoms severity, 8 patients (14.3%) in Group A referred moderate symptoms (no patients had severe symptoms), whilst 19 patients (34.5%) in Group B still had moderate-to-severe symptoms (2/19 had severe symptoms) (p = 0.01). Urinalysis parameters and rate of positive urine cultures were not statistically significantly different (Table 2 and Figure 3).

Finally, no statistically significant differences were found in $Q_{max}$ and PVR.

4. Discussion

The present single-center randomized controlled phase III trial investigated for the first time the efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms and prevention of lower urinary tract infections in patients undergoing ThuLEP.

After accounting for exclusion criteria, 111 patients were randomized (56 received Mictalase® versus 55 controls). Randomization performed well, with no differences at baseline between groups. Notably, although randomization would have been unable to control for intra-operative and peri-operative factors, no statistically significant differences were found between the groups. Moreover, ThuLEP performed similarly in relieving from BPO whatever the Group.

Concerning the study endpoints, improvement of IPSS at 30 days postoperation was more pronounced in patients who received Mictalase®. Moreover, a lower rate of positive urine culture at 15 days postoperatively favored the Mictalase® group.

To the best of our knowledge, no study investigated the use of Phenolmicin P3 and/or Bosexil, either alone or in combination to manage the post-operative irritative symptoms after transurethral prostate surgeries.

Even after expanding the search strings, to let the adoption of suppositories with different active principles being included, there are anecdotal studies in the field.

Within a prospective randomized controlled study, Ergakov et al. tested the efficacy of rectal suppository based on Serenoa repens, selenium and lycopene in association with antibiotics for prevention of infectious-inflammatory complications after TURP [21]. The authors found a statistically significant reduction in patient-reported outcomes (IPSS and QoL) in the treated group (11.5 +/- 1.2 and 2.6 +/- 0.3 points, respectively) compared with controls (15.5 +/- 1.4 and 3.8 +/- 0.5 points, respectively). Another study investigating the effects of the same medical device was published by Nozdrachev et al. who, by mean of inflammatory changes measured in postoperative blood and urine samples, and renal microcirculation including variations in perfusion intensity and renal ischemia and congestion, observed favorable response after administration of the suppository [22].
Other than the referenced experiences, no studies of interest were retrieved in our literature search. It is important to underline that the active principles included in the suppositories tested within the setting of the aforementioned studies (namely Serenoa repens, selenium and lycopene) are a well-known combination in the management of prostate-related symptoms. Furthermore, differently from the mentioned studies, we did not include the use of prolonged antibiotic prophylaxis in association with the investigated suppository.

The suppository we herein investigated includes different active principles, namely: Bosexil®, that is a vegetal extract derived from the resin of the *Boswellia serrata*, a plant native to India. It has already been published that the Boswellic acids contained show anti-inflammatory and antioxidant properties in a variety of inflammatory diseases whose physio-pathological pathways are shared with those of prostatitis [23, 24]; phenolmicin P3 is a polyphenolic extract derived from beehive propolis, that also demonstrated anti-inflammatory and antioxidant properties in preclinical reports. It has also been reported to have the ability to create a microenvironment hostile to the reproduction of pathogenic bacteria. Indeed, one of the most important etiological agents of inflammatory diseases is the cause-and-effect relationship between oxygen free radicals and oxidative damage at the biomolecular level. [25–27]. Actually, the efficacy of the transrectal delivered association of Boswellia resin extract and propolis derived polyphenols in relieving prostatitis-like symptoms was tested by another research group [28]. As assessed by standardised questionnaires, the suppository was found able to reduce genitourinary pain and to improve quality of life in men affected by bothersome prostatitis-like symptoms.

In our randomized study, the suppository Mictalase® seemed to impact on the improvement in IPSS. The assessment of this patient-reported outcome after transurethral laser BPH surgery can be influenced by preoperative patient’s conditions and unmodifiable parameters (mostly PVol), intraoperative variables (mostly the total energy delivered), and postoperative factors (mostly the catheterization time and the occurrence of infections). Of note, even if most of the perioperative / postoperative variables would have remained uncontrolled by randomization, treatment groups did not significantly differ. Thus, it is hard to conclude that the differences we observed were due to chance.

Another relevant finding from our study is the incidence of postoperative urinary infections as assessed by urine culture. Notwithstanding the known anti-microbial properties of phenolmicin P3, the exact mechanism of impact on the urine culture outcome is unclear. On the other hand, we observed that, in the setting of a randomized trial, clinically-significant urinary infections (requiring antibiotics) were anecdotal when Mictalase® was administered. This is interesting in the modern era, in which the abuse of antibiotic is discouraged by guidelines, due to epidemiological and socio-economics reasons [29]. The data we report herein would support the avoided routine use of antimicrobial prophylaxis beyond the perioperative single-shot even in the case of transurethral endoscopic procedure for BPH management [30].

Drafting conclusive recommendations on how to manage patients presenting with dysuria and/or pelvic pain and/or prostatodynia after transurethral prostate surgery still represents a challenge in endourology. Such syndrome remains of unclear patho-phisiology, thus being a driver for stimulating further research.
On the other hand, although the rigorous methodology, given the number of actors playing a role in the complexity of post-transurethral prostate surgery syndrome, our study could have been underpowered in detecting other variables / effects. Moreover, the open label study design could have supersized the positive effect on irritative symptoms perceived in the treatment group.

More data about the actual impact of the combination of Phenolmicin P3 and Bosexil on the irritative symptoms and urinary infections in patients undergoing transurethral prostate surgery are warranted.

5. Conclusions

The present randomized trial investigated for the first time the efficacy of the Mictalase® suppositories in the symptoms control and prevention of lower urinary tract infections in patients undergoing ThuLEP. Concerning the study endpoints, improvement of IPSS at 30 days postoperation was more pronounced in patients who received Mictalase®. Moreover, a lower rate of positive urine culture at 15 days postoperatively favored the Mictalase® group.

Abbreviations

Lower urinary tract symptoms (LUTS)
benign prostatic hyperplasia (BPH)
benign prostatic obstruction (BPO)
transurethral resection of the prostate (TURP)
open prostatectomy (OP)
endoscopic enucleation of the prostate (EEP)
thulium laser enucleation of prostate (ThuLEP)
prostate volume (PVol)
maximum urinary flow rate at uroflowmetry ($Q_{\text{max}}$)
post-voiding residual volume (PVR)
International Prostate Symptom Score (IPSS)
Quality of Life (QoL)
interquartile ranges (IQR)

Declarations
Ethics approval and consent to participate

The study was approved by the local institutional ethics committee of San Camillo Forlanini Hospital (no. approval STS CE Lazio 1/N-726) and performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. Informed consent was obtained from all subjects and/or their legal guardian(s).

Consent for publication

Written informed consent for publication has been obtained from participants involved in the present study.

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available [due to their containing information that could compromise the privacy of research participants] but are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

Lampugnani Farmaceutici S.p.A. (Nerviano, Milan, Italy) provided the suppositories free of charge to the patients involved in the present study.

Authors' contributions

RB, CC, PB: conception of the study

RB, CC, PB: study design

RB, CC, MV, MC, FM, VI, MA, MS, FP, MP: acquisition, analysis, interpretation of data

RB, CG, PB drafting of the manuscript / revision

Acknowledgements

Not applicable.

References


Tables

Table 1
Distribution of baseline characteristics, peri-operative and post-operative outcomes of patients in the treatment groups.

<table>
<thead>
<tr>
<th></th>
<th>Mictalase Group n = 56</th>
<th>Control Group n = 55</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patients’ baseline characteristics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>65 (61-75)</td>
<td>69 (63 - 74)</td>
<td>0.2</td>
</tr>
<tr>
<td>PVol, ml</td>
<td>73.5 (50.0 – 90.0)</td>
<td>70.0 (50.0 – 100.0)</td>
<td>0.7</td>
</tr>
<tr>
<td>Q_{\text{max}}, ml/s</td>
<td>10.0 (8.0 - 13.7)</td>
<td>9.4 (7.0 - 12.1)</td>
<td>0.4</td>
</tr>
<tr>
<td>PVR, ml</td>
<td>65 (40 - 100)</td>
<td>90 (70 - 110)</td>
<td>0.5</td>
</tr>
<tr>
<td>IPSS</td>
<td>21 (16 - 26)</td>
<td>23 (19 - 28)</td>
<td>0.3</td>
</tr>
<tr>
<td>QoL</td>
<td>5 (4 - 5)</td>
<td>5 (4 - 6)</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>Intra-operative data</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operative Time, min</td>
<td>88 (70 - 125)</td>
<td>102 (75 - 138)</td>
<td>0.6</td>
</tr>
<tr>
<td>Energy delivered, joules</td>
<td>58k (42k- 83k)</td>
<td>60k (44k – 80k)</td>
<td>0.9</td>
</tr>
<tr>
<td>Complications</td>
<td>0 (0)</td>
<td>1 (1.8)</td>
<td>0.3</td>
</tr>
<tr>
<td><strong>Peri-operative data</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Length of stay, days</td>
<td>3 (2 - 3)</td>
<td>3 (3 - 4)</td>
<td>0.1</td>
</tr>
<tr>
<td>Catheterization time, days</td>
<td>3 (2 - 5)</td>
<td>3 (2 - 5)</td>
<td>0.1</td>
</tr>
<tr>
<td>Complications</td>
<td>2 (3.6)</td>
<td>3 (5.4)</td>
<td>0.6</td>
</tr>
</tbody>
</table>

Median is reported for continuous variables, while number of observations is reported for categorical variables. Inter-Quartile Range (IQR) and percentages are reported in brackets, as appropriate. PVol: Prostate Volume; Q_{max}: Maximum urinary flow rate at uroflowmetry; PVR: Post-Voiding Residual Volume; IPSS: International Prostate Symptom score; QoL: Quality of Life.
Table 2
Distribution of post-operative outcomes in the treatment groups. Median is reported for continuous variables, while number of observations is reported for categorical variables. Inter-Quartile Range (IQR) and percentages are reported in brackets, as appropriate. IPSS: International Prostate Symptom score; QoL: Quality of Life; WBC: white blood cells; HPF: high power field; RBC: red blood cells, $Q_{\text{max}}$: Maximum Urinary Flow rate at uroflowmetry; PVR: Post-Voiding Residual volume.

<table>
<thead>
<tr>
<th></th>
<th>Mictalase Group n = 56</th>
<th>Control Group n = 55</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>15th postoperative day follow-up</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IPSS</td>
<td>12 (6 - 16)</td>
<td>10 (7 - 15)</td>
<td>0.7</td>
</tr>
<tr>
<td>QoL</td>
<td>2 (1 - 4)</td>
<td>2 (1 - 3)</td>
<td>0.1</td>
</tr>
<tr>
<td>Urine pH</td>
<td>6.5 (5.5 - 6.5)</td>
<td>5.5 (5.5 - 6.5)</td>
<td>0.4</td>
</tr>
<tr>
<td>WBC-sediment (counts/HPF)</td>
<td>90 (30 - 250)</td>
<td>55 (30 - 134)</td>
<td>0.4</td>
</tr>
<tr>
<td>RBC-sediment (counts/HPF)</td>
<td>90 (39 - 450)</td>
<td>66 (15 - 431)</td>
<td>0.5</td>
</tr>
<tr>
<td>Urine specific gravity</td>
<td>1013 (1008 - 1018)</td>
<td>1015 (1011 - 1020)</td>
<td>0.3</td>
</tr>
<tr>
<td>Positive urine culture</td>
<td>3 (2.7)</td>
<td>10 (9.0)</td>
<td>0.04</td>
</tr>
<tr>
<td>30th postoperative day follow-up</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IPSS</td>
<td>6 (3 - 11)</td>
<td>10 (5 - 13)</td>
<td>0.02</td>
</tr>
<tr>
<td>QoL</td>
<td>2 (1 - 3)</td>
<td>2 (1 - 4)</td>
<td>0.1</td>
</tr>
<tr>
<td>Urine pH</td>
<td>5.5 (5.5 - 7.0)</td>
<td>5.5 (5.0 - 6.0)</td>
<td>0.2</td>
</tr>
<tr>
<td>WBC-sediment (counts/HPF)</td>
<td>70 (11 - 138)</td>
<td>36 (25 - 81)</td>
<td>0.8</td>
</tr>
<tr>
<td>RBC-sediment (counts/HPF)</td>
<td>16 (7 - 65)</td>
<td>20 (8 - 113)</td>
<td>0.4</td>
</tr>
<tr>
<td>Urine specific gravity</td>
<td>1015 (1015 - 1019)</td>
<td>1014 (1010 - 1021)</td>
<td>0.9</td>
</tr>
<tr>
<td>Positive urine culture</td>
<td>1 (0.9)</td>
<td>1 (0.9)</td>
<td>1</td>
</tr>
<tr>
<td>$Q_{\text{max}}$, ml/s</td>
<td>22.1 (19.0 - 28.2)</td>
<td>22.8 (16.4 - 25.2)</td>
<td>0.4</td>
</tr>
<tr>
<td>PVR, ml</td>
<td>0 (0 - 0)</td>
<td>0 (0 - 0)</td>
<td>0.6</td>
</tr>
</tbody>
</table>
Figure 1

Study CONSORT checklist (available at www.consort-statement.org).

Figure 2

Study Flow-Chart.

Figure 3

2 x 2 tables reporting urine culture data across treatment groups at 15\textsuperscript{th} and 30\textsuperscript{th} postoperative day (POD).

*after excluding asymptomatic bacteriuria.

Figure 4

Box plot depicting the International Prostate Symptom Score (IPSS) in the groups (Group A – Mictalase\textsuperscript{®} versus Group B - controls) at baseline, 15\textsuperscript{th} and 30\textsuperscript{th} postoperative day assessments.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryFigure1.tiff
- SupplementaryFigure2.tiff